EUCTR2019-002291-13-FR进行中（未招募）1 期
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •101. Histologically confirmed large B-cell lymphoma, including the following types defined by WHO 2016 (Swerdlow et al, 2016):
- •? - Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including Germinal center B-cell (GCB) type and activated B-cell (ABC) type; Intravascular large B-cell lymphoma; T-cell/histiocyte-rich large B-cell lymphoma; DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV + DLBCL, NOS;
- •? - High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit)
- •? - High-grade B-cell lymphoma, NOS
- •102. High risk large B-cell lymphoma, defined as one or more of the following:
- •? High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations (double-hit or triple-hit) as determined by investigator by fluorescent in situ hybridization (FISH)
- •? International Prognostic Index (IPI) score of =3 at initial diagnosis or anytime between initial diagnosis and enrolment
- •103. Subjects must have a positive interim PET per Cheson, 2014 (Deauville PET score of 4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy as follows:
- •? 2 cycles of a dose intense anti-CD20 monoclonal antibody and anthracycline containing regimen (e.g. DA-EPOCH-R) x 2 cycles with or without intrathecal chemotherapy at the discretion of the investigator per standard of care for double-hit or triple-hit lymphoma
- •? 2 cycles of a standard anti-CD20 monoclonal antibody and anthracycline containing regimen (e.g. R-CHOP) for large B-cell lymphoma with IPI score of =3
- •104. At least 2 weeks must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis
- •105. No evidence, suspicion and/or history of CNS involvement of lymphoma
- •106. Toxicities due to prior therapy must be stable and recovered to = Grade 1 (except for clinically non-significant toxicities such as alopecia)
- •107. Age 18 or older
- •108. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •109. ANC = 1000/µL
- •110. Platelet count = 75,000/µL
- •111. Absolute lymphocyte count = 100/µL
- •112. Adequate renal, hepatic, pulmonary, and cardiac function defined as:
- •a. Creatinine clearance (as estimated by Cockcroft Gault) = 60 mL/min
- •b. Serum ALT/AST =2.5 ULN
- •c. Total bilirubin =1.5 mg/dL, except in subjects with Gilbert’s syndrome
- •113. Cardiac ejection fraction = 50% , no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
- •114. No clinically significant pleural effusion
- •115. Baseline oxygen saturation > 92% on room air
- •116. Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •201. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg cervix, bladder, breast) unless disease free for at least 3 years
- •202. History of Richter’s transformation of CLL or PMBCL
- •203. History of autologous or allogeneic stem cell transplant
- •204. Prior CD19-targeted therapy
- •205. Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy
- •206. History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
- •207. Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management; simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the sponsor’s medical monitor
- •208. History of HIV infection or acute or chronic active hepatitis B or C infection; subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines or applicable country guidelines
- •209. Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter); dedicated central venous access catheters, such as a Port-a-Cath or Hickman catheter, are permitted
- •210. Subjects with detectable cerebrospinal fluid malignant cells, brain metastases, or active CNS lymphoma
- •211. History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
- •212. Subjects with cardiac atrial or cardiac ventricular lymphoma involvement
- •213. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
- •214. Requirement for urgent therapy due to tumor mass effects (eg, blood vessel compression, bowel obstruction, or transmural gastric involvement)
- •215. Primary immunodeficiency
- •216. History of autoimmune disease (eg, Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years
- •217. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment
- •218. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
- •219. History of severe immediate hypersensitivity reaction to any of the agents used in this study
- •220. Live vaccine = 6 weeks prior to planned start of conditioning regimen
- •221. Women of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been postmenopausal for
- •at least 2 years are not considered to be of childbearing potential
- •222. Subjects of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion of conditioning chemotherapy
- •223. In the investigator’s judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
研究者
相似试验
进行中（未招募）
1 期
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)CTIS2023-506641-35-00Kite Pharma Inc.183
进行中（未招募）
1 期
A Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)Relapsed/Refractory Mantle Cell Lymphoma (MCL)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005008-27-ESKite Pharma, Inc.220
进行中（未招募）
1 期
A Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)Relapsed/Refractory Mantle Cell Lymphoma (MCL)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005008-27-NLKite Pharma, Inc.220
进行中（未招募）
1 期
A Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)Relapsed/Refractory Mantle Cell Lymphoma (MCL)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005008-27-FRKite Pharma Inc.70
招募中
2 期
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)Mantle Cell Lymphoma (MCL)cancer of white blood cells10025322NL-OMON54549Kite Pharma Inc.20